NEW YORK — Mylan Pharmaceuticals Inc., Actavis Inc. and Teva Pharmaceutical Industries Ltd. this week began shipping generic versions of the branded drug Flomax, for the treatment of enlarged prostate.

Mylan and Teva said Wednesday they received final approval from the Food and Drug Administration for 0.4 mg tamsulosin hydrochloride capsules, the generic version of Boehringer-Ingelheim’s Flomax medication for the treatment of benign prostatic hyperplasia.

Actavis said it’s partnering with Synthon Pharmaceuticals to launch and market tamsulosin capsules in the United States.

Citing IMS Health data, the three companies reported tamsulosin hydrochloride capsules had U.S. sales of more than $2 billion last year.